Advancing Biomarker Qualification: FDA Perspective on Efficiency, Surrogate Endpoints, and Future Directions
Crossref DOI link: https://doi.org/10.1007/s43441-025-00911-x
Published Online: 2026-02-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sekar, Vanitha
Siegel, Jeffrey
Text and Data Mining valid from 2026-02-10
Version of Record valid from 2026-02-10
Article History
Received: 1 December 2025
Accepted: 22 December 2025
First Online: 10 February 2026
Declarations
:
: The authors declare no competing interests.